GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chromocell Therapeutics Corp (AMEX:CHRO) » Definitions » PensionAndRetirementBenefit

Chromocell Therapeutics (Chromocell Therapeutics) PensionAndRetirementBenefit : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Chromocell Therapeutics PensionAndRetirementBenefit?

Chromocell Therapeutics's PensionAndRetirementBenefit for the quarter that ended in Mar. 2024 was $0.00 Mil.


Chromocell Therapeutics PensionAndRetirementBenefit Historical Data

The historical data trend for Chromocell Therapeutics's PensionAndRetirementBenefit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chromocell Therapeutics PensionAndRetirementBenefit Chart

Chromocell Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
PensionAndRetirementBenefit
- - - -

Chromocell Therapeutics Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PensionAndRetirementBenefit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Chromocell Therapeutics PensionAndRetirementBenefit Calculation

PensionAndRetirementBenefit is the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.


Chromocell Therapeutics (Chromocell Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Chromocell Therapeutics Corp is a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Its clinical focus is to selectively target the sodium ion-channel known as "NaV1.7", as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology.

Chromocell Therapeutics (Chromocell Therapeutics) Headlines